ALLO News and Press, Allogene Therapeutics Inc. From 04/25/23

Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for ...

Former Kite Pharma Executive Responsible for the Development and Commercial Launch of Two of the Most Successful Autologous CAR T Manufacturing Processes in the Industry Brings Unique Experience as a CAR T Pioneer in Advancing Next Generation Biocellular Production Processes to Support Comm...

Data Provide Proof-of-Concept for an Allogeneic Anti-CD70 CAR T Candidate in Patients with Renal Cell Carcinoma (RCC) Who Received Prior Immune Checkpoint Inhibitor and VEGF-Targeting Therapy Single Infusion of ALLO-316 Demonstrates Promising Anti-Tumor Activity in CD70 Expressing RCC T...

SOUTH SAN FRANCISCO, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in four upcoming inve...

SOUTH SAN FRANCISCO, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today published its 2022 annual ESG report . The report pr...

Initial Data Provide Proof-of-Concept for an anti-CD70 AlloCAR T Candidate in Patients with Renal Cell Carcinoma (RCC) Who Received Prior Immune Checkpoint Inhibitor and VEGF-Targeting Therapy ALLO-316 Data Also Highlight the Potential of Dagger™ Technology, a Next Generation Allogenei...

2023-03-10 17:31:23 ET Amid concerns about smaller pharma and biotech companies' exposure to Silicon Valley Bank ( SIVB ), a number of them have disclosed that they have no relationship with the FDIC-shuttered financial institution . Among the larger ones are Cara Therapeu...

Summary Allogene Therapeutics presents an attractive investment opportunity in the biotechnology sector due to its focus on developing allogeneic CAR T products for cancer treatment. The recent announcement of preclinical data demonstrating the effectiveness of its Dagger platform techn...

Publication Reviews Investigation of a Chromosomal Rearrangement Observed in a Single Patient Receiving Gene-Edited Allogeneic CAR T Treatment for Large B Cell Lymphoma Case Reveals Normal T Cell Biology Occurring in CAR T Cells, Including Notable Finding of Continued Chromosomal Rearrangemen...

Allogene Therapeutics, Inc. (ALLO) Q4 2022 Earnings Conference Call February 28, 2023, 17:00 ET Company Participants Christine Cassiano - Chief Communications Officer David Chang - Co-Founder, President, CEO & Director Zachary Roberts - EVP, Research & Developm...